Navigation Links
Amicus Therapeutics Announces Third Quarter 2010 Financial Results
Date:11/8/2010

CRANBURY, N.J., Nov. 8, 2010 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced financial results for the quarter ended September 30, 2010, provided an update on its product development pipeline, including its Phase 3 program with Amigal (migalastat HCl) for the treatment of Fabry disease and reaffirmed the financial strength of the Company.  

John F. Crowley, Chairman and CEO of Amicus Therapeutics stated, "During the third quarter we made significant progress further establishing Amicus as a leader in the research and development of new treatments for rare diseases.  Our strategic partnership with GSK not only supports the potential for success with the Amigal program but also provides us with multiple strategic options for continued growth.  Moving forward, we intend to judiciously invest in our pipeline and to explore a series of additional partnerships, all while ensuring that our financial strength allows us to fund our operations and capital expenditures through the anticipated U.S. commercial launch of Amigal."

Third Quarter Financial SummaryAs of September 30, 2010, Amicus held $57.6 million of cash, cash equivalents, and marketable securities.

For the three months ended September 30, 2010, Amicus reported a net loss of $15.4 million, or $0.56 per share attributable to common stockholders, compared to a net loss of $13.4 million, or $0.59 per share attributable to common stockholders for the same period in 2009.

Pipeline OverviewAmigal (migalastat HCl) for the Treatment of Fabry DiseaseOn October 29, 2010, Amicus announced a definitive agreement with GlaxoSmithKline PLC (GSK) to develop and commercialize Amigal™ (migalastat HCl), currently in Phase 3 for the treatment of Fabry disease.  Under the terms of the agreement, GSK received an exclusive worldwide license to d
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
2. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
3. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
4. Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing
5. Alzheimers Drug Discovery Foundation Funds Amicus Therapeutics To Advance Pharmacological Chaperone Technology
6. Fenwal Receives FDA Clearance for Amicus(R) Separator With Wireless Connectivity
7. Amicus Therapeutics to Host its First Quarter 2010 Financial Results Conference Call and Webcast on May 6, 2010
8. FDA Clears the Fenwal Amicus(R) Separator System for Collecting Platelets in New Additive Solution
9. Amicus Therapeutics Announces Closing of $18.5 Million Registered Direct Offering of Common Stock
10. Amicus Therapeutics Announces $18.5 Million Registered Direct Offering of Common Stock
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 1, 2014 Quantum Materials Corp (OTCQB:QTMM) ... of photoactive quantum dots for use in ... numerous advantages for solar power generation, the high ... quantum dots with which to develop thin film ... commercial utilization and acceptance. The company is also ...
(Date:10/1/2014)... -- CVS Health is thanking its 26,000 pharmacists during October,s ... way health care is delivered to increase access, lower ... mail service pharmacies and specialty pharmacies nationwide.  ... CVS Health to reflect our broader health care commitment ... shape the future of health," said Larry Merlo ...
(Date:9/30/2014)... LONDON , Sept. 30, 2014 This report ... Million by the following Product Categories: Enteral Feeding Pumps, Nasogastric ... analytics for the US Canada, Japan , ... Latin America , and Rest of World. ... through 2018. Also, a six-year historic analysis is provided for ...
Breaking Medicine Technology:Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19
... TEMPE, Ariz., Oct. 27 Intrinsic Bioprobes today ... Office has issued US Patent 7,816,095 covering novel ... patent is first of a series of patent ... biomarkers with clinical utility. "The biomarkers ...
... Boston Scientific Corporation (NYSE: BSX ) ... Asthmatx, Inc. of Sunnyvale, California.  The transaction follows ... the terms of the agreement, Boston Scientific purchased ... $193.5 million.  Additional payments of up to $250 ...
Cached Medicine Technology:Intrinsic Bioprobes Announces Issuance of US Patent for Novel Biomarkers and Assays for Myocardial Infarction 2Boston Scientific Completes Acquisition of Asthmatx 2Boston Scientific Completes Acquisition of Asthmatx 3
(Date:10/1/2014)... of the human eye, the brain of a rat ... new technology, says a QUT leading robotics researcher. ... Faculty says the new study uses new computer algorithms ... buildings or tunnels. , "This is a very Frankenstein ... two halves of a thing together because we,re taking ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog post explaining how ... Senior citizens can qualify for affordable term life insurance ... are over 50 years old. Some term life insurance ... , Term life insurance with a simplified issue can ... life insurance during retirement is important for covering funeral ...
(Date:10/1/2014)... Nev. (PRWEB) October 01, 2014 First ... measuring abnormal circadian cellular changes throughout the body, announced ... Inc. to better address the company’s breadth of upcoming ... early breast cancer screening technology. , “Our initial focus ... cancer system which detects abnormal circadian cellular changes over ...
(Date:10/1/2014)... A new genetic finding from Duke Medicine suggests that ... depression might also be hard-wired to gain weight when ... disease. , An estimated 13 percent of people, all ... and knowing this could help them reduce heart disease ... and stress management. , "Genetic susceptibility, psychosocial stress and ...
(Date:10/1/2014)... NoteSwift Inc., announced today their new ... and 13.0. NoteSwift is the bridge between the EHR ... and document clinical information at the point of care. ... patient note by more than half – and virtually ... points providers state impedes EHR use according to the ...
Breaking Medicine News(10 mins):Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3
... who get married lead a happier life than people who ... more complex than this, according to a long-running population study ... has no impact on that general life satisfaction. on contrary ... over the years irrespective of whether a person is married ...
... list that travelers should avoid because of SARS. The local ... stunned by this. Toronto is the first locality outside China ... of the respiratory disease. Beijing and Shanxi Province in China ... Kong and Guangdong Province as the hot spots for severe ...
... basis help protect patients from Heart disease. Tea consumption ... a heart attack.,Researchers said that the protection appears to ... are plentiful in both black and green tea. Flavonoids ... apples, onions, and broccoli. Drinking tea helped the blood ...
... may probably be small if the trip isn't to Asia. ... about the virus. However people can be comfortable in the ... have even been policies implemented to keep travel as harmless ... systems that has stringent filters to screen out spores, bacteria ...
... 300pc rise in the number of people affected by Type ... a little high. In a new report from the DRWF ... is to occur. If left untreated or mismanaged the condition ... is also estimated that 1m people nationally are unaware they ...
... have an detrimental effect on infant's brain, reducing its ... reason behind increasing language learning disorders. With increase in ... baby's sensitive developing brain could be damaged. In an ... auditory cortex, in a growing rat's brain undergoes swift ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: